Standigm, a prominent workflow artificial intelligence (AI) drug discovery company, recently signed a Memorandum of Understanding (MOU) with Institut Pasteur Korea (IPK), the infectious disease-focused research organization contributing to public health, for AI-based drug discovery study for infectious disease.
- Combine Standigm's AI drug discovery platform and Institut Pasteur Korea's research expertise in infectious disease - Accelerate discovery of novel anti-tubercular drug candidates by conducting RIGHT Fund's awarded projects SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding.